This study is testing a new way to prepare patients for an allogeneic hematopoietic stem cell transplant (AHSCT), which is a treatment for blood cancers like leukemia and lymphoma. You would receive a combination of medicines called fludarabine and melphalan, plus radiation therapy called total body irradiation (TBI). The doses of melphalan and TBI will be adjusted based on your individual risk factors. The study aims to see how well this approach prevents the cancer from coming back (progression-free survival) over four years. We are looking for 60 participants, aged 18 to 70, with certain blood cancers who need an AHSCT and have a suitable donor. The study status is currently unclear.

Study design

This is a single-arm study, meaning all 60 participants will receive the same treatment approach. It is a Phase II study.

What's involved

Eligible patients will receive an allogeneic stem cell transplantation with specific conditioning and post-transplant medications.

Compensation

Not stated in the trial record.

Follow-up

All patients will be monitored for safety and efficacy for up to 2 years after the transplant, with progression-free survival measured up to 48 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.